Precision medicine strives to delineate disease using multiple data sources-from genomics to digital health metrics-in order to be more precise and accurate in our diagnoses, definitions, and treatments of disease subtypes. By defining disease at a deeper level, we can treat patients based on an understanding of the molecular underpinnings of their presentations, rather than grouping patients into broad categories with one-size-fits-all treatments. In this review, the authors examine how precision medicine, specifically that surrounding genetic testing and genetic therapeutics, has begun to make strides in both common and rare cardiovascular diseases in the clinic and the laboratory, and how these advances are beginning to enable us to more effectively define risk, diagnose disease, and deliver therapeutics for each individual patient. (J Am Coll Cardiol Basic Trans Science 2018;3:313-26)
history, imaging, genomics, proteomics, metabolomics, sensor data, and more. In being both more precise and more accurate in our diagnosis and in our definitions of subtypes of disease, we can treat patients based on the true underpinnings of their specific presentations, rather than grouping patients into broad categories with one-size-fits-all treatment. The goal of this strategy is not only to give patients more efficient and effective care, but also to reduce patient harm and limit health care costs arising from unnecessary or inappropriate treatment.
In this review, we discuss existing successes of precision medicine in multiple clinical areas and their implications in cardiovascular medicine. We then examine how precision medicine, most specifically that surrounding genetic testing and genetic therapeutics, has begun to make strides in both common and rare cardiovascular diseases (CVDs). In addition, we examine how basic research, including the use of induced pluripotent stem cells (iPSCs), is advancing precision cardiovascular medicine.
LESSONS FROM PRECISION MEDICINE IN ONCOLOGY AND CYSTIC FIBROSIS
Precision medicine has already made significant strides in patient care, bolstering support for its po- Although there are >100 disease-associated CFTR mutations, they can be grouped into classes based on their effects on the protein (5) . Molecular therapeutics can now be used to target the defects representative of 2 of these classes: CFTR regulation (Class III) and CFTR processing (Class II).
Ivacaftor, a drug that targeted a specific class III mutation, showed benefits in preclinical and clinical trials due to careful patient selection. Participants were selected based on the presence of the target mutation and showed dramatic improvements in CF symptoms, including a reversal of chronic sinusitis and improvement in lung function as measured by nasal potential difference, as well as unforeseen benefits in overall health, such as positive weight gain (5).
However, had clinical trial drugs been administered to all CF patients, overall benefits would likely have been low, and the clinical trial might have failed, despite positive benefits in the true target participants (5).
This lesson of appropriate participant and patient selection in precision medicine trials is a lesson that should be carried into cardiovascular precision medicine. A recent report suggested that many failed chronic heart failure trials might have instead been successes if patients were more carefully chosen based on precise biomarkers linked to action of each therapeutic (6) . Defining disease at a molecular level to treat it more precisely would improve not only clinical trial outcomes but also patient care and will become increasingly possible as we learn more about genetic associations with disease through continued adoption of and research studying clinical genetic sequencing.
Increased investigation of sequencing data will allow us to better link the genotype of a patient, that is, the collection of genetic variants they possess that influence their condition, with their disease phenotype, its observable characteristics, and its presentation.
CLINICAL APPLICABILITY OF GENETIC TESTING IN CVD AND PRECISION MEDICINE
The cost of genetic testing has fallen dramatically over the past decade due to major advances in sequencing technology, in particular, the advent of nextgeneration sequencing (NGS). As the cost of NGS continues to fall and more potential disease-associated and disease-causing variants are identified, clinical genetic testing is becoming more common and more informative. Although genetic therapy and testing are not the only routes toward precision medicine, their increasing presence and usefulness have positioned them at the forefront of many discussions surrounding precision medicine, including this review.
In 2010, we introduced an approach to the evaluation of a personal genome in a clinical context (7) .
A patient with a family history of coronary artery 
disease (CAD) and sudden death was evaluated by a cardiac clinical team in conjunction with whole genome sequencing and interpretation. The genomic analysis revealed an increased genetic risk for myocardial infarction and type 2 diabetes. In addition, a pharmacogenomics analysis was performed to assess how the genetics of the patient might influence response to certain drugs, including lipid-lowering therapies and warfarin (7) . This clinical assessment, which focused heavily on cardiovascular risk, suggested that whole genome sequencing might provide clinically relevant information for patients. Similarly, a statement from the American Heart Association and the American College of Cardiology recommended genetic testing for HCM, DCM, and thoracic aortic aneurysms to facilitate familial cascade screening and deduce causative mutations (9,10).
The diagnostic power of genetic testing is significant across the spectrum of CVDs, ranging from cardiomyopathies to life-threatening arrhythmias (10) (11) (12) . In the clinic, genetic testing can: 
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identical CaM proteins (CALM1, CALM2, or CALM3), silencing or reducing expression of the gene could relieve the disease phenotype (27) . In almost all cases in which CaM mutations cause disease, they do so by The study randomized participants without CAD to 1 of 2 groups. The first received a 10-year estimation of risk of CAD calculated from a CRS alone, whereas the second group received a CRS plus a CAD-specific GRS.
The GRS group received risk information from a genetic counselor and also met with a physician for shared decision-making regarding statin therapy (34) .
At the end of the study period, the group that had received GRS information had a significantly lowered LDL-C level than the plain CRS group. They were also more likely to be using statins at this final checkup, although this effect was likely due to increased prescription recommendation from the doctors (39.2%
vs. 21.9%; p < 0.01). The study found no effect of GRS on lifestyle behaviors (e.g., dietary fat intake or physical activity levels), but it also found no increase in patient anxiety (34, 36) . The research group reported in separate studies that patients who received the GRS had slightly higher perceived personal control and genetic counseling satisfaction (37) and that patients who received a GRS were more likely at 6 months post-disclosure to have sought out additional information about coronary heart disease (CHD) and genetic risk factors of CHD than patients who received a CRS (38) . Although the study was limited by lack of physician blinding and included genetic information from only 11 SNPs, it provided an important example of a GRS affecting clinical measures, underscoring the potential of such information to change practitioner prescribing behavior.
Although the MI-GENES study could not differentiate between effect on the patient versus effect on the health care provider, a more recent study by Knowles et al. (39) looked at the usefulness of GRS as a motivational tool for reducing CAD risk factors.
Patients who received standard-of-care plus GRS
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Cardiovascular Precision Medicine in the Genomics Era showed no significant changes, including medication use, blood pressure, physical activity, weight, and high-density lipoprotein concentration compared with standard-of-care patients (39) . Although modest beneficial effects were seen in physical activity and weight loss in a subgroup of patients with a high GRS, and the study showed no negative psychological effects of adding GRS to standard-of-care treatment, the investigators noted that a larger study is needed to refute or confirm their findings (39).
In the MI-GENES study, a GRS was used to inte- The researchers found that those with a high GRS had a 91% higher relative risk of incident coronary events than those with a low GRS (42) .
To assess the association of lifestyle behaviors and risk of coronary events, the investigators also scored each individual for adherence to 4 healthy lifestyle behaviors described by the American Heart Associa- were correlated with lower LDL levels (45, 46) . This lifelong decrease in LDL levels due to decreased function of PCSK9 reduced the risk of CHD by up to 88%, a greater benefit than that conferred by shortterm statin treatment (45, 47, 48) .
This finding that decreased PCSK9 levels could not only have direct effects on LDL levels but also broader effects on CHD risk suggested that reducing levels of PCSK9 activity might provide therapeutic benefits.
This reduction could be induced in patients using PCSK9 therapeutic inhibitors, monoclonal antibodybased drugs that target PCSK9 and attempt to reduce its activity. These antibody inhibitors bind to PCSK9
with high affinity and disrupt its ability to bind to the LDL receptor. This leaves more of the receptor available on the cell surface, which is then able to pull more LDL out of the blood, thus lowering overall levels and reducing the risk of CVD. In a review of long-term studies, PCSK9 inhibitors versus placebo showed a >50% decrease in LDL-C levels at 24 weeks and 30% to 40% decrease compared with current medical treatments, together with a decreased risk of CVD, although they showed little to no effect on allcause mortality (49).
PCKS9 inhibition at the level of RNA rather than protein has also shown promise in clinical trials.
Inclisiran, a long-acting siRNA that targets As clinical genome sequencing becomes more common and basic science techniques like CRISPR and induced pluripotent stem cells begin to transition toward clinical applicability, the world of cardiovascular medicine moves toward one where we can be more precise and accurate with our diagnoses and treatment. Using knowledge gained from population sequencing projects, such as genome-wide association studies, and disease models in the laboratory, we can begin to develop deeper understandings of disease at a molecular level to predict the risk of a patient for developing a disease and present them with the right treatment when they do-or the right preventative strategy in advance.
This review focuses on how precision medicine, genomics, and new genetic tools intertwine to create a new era of cardiovascular precision medicine. FH ¼ familial hypercholesterolemia; HC ¼ hypertrophic cardiomyopathy; iPSC ¼ induced pluripotent stem cells; LQTS ¼ long QT syndrome. surrounding what kinds of edits we as a society will decide are appropriate or inappropriate to make, it highlights the fact that there is still much discussion to be had and scientific exploration to be done surrounding this topic before moving forward. Conversely, variants that may be common in less studied populations may be falsely classified as pathogenic variants, invalidating cascade screening in family members and leading to misdiagnoses (80) .
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 3 , N O . 2 , 2 0 1 8

Dainis and Ashley
Although more studies have begun to investigate variant effects across diverse populations, we should strive for even greater adoption of this necessary inclusion across study designs. Recent papers addressing these concerns, including the study by Hindorff et al. (81) , highlight the need for community engagement to overcome study enrollment obstacles and further stress that diverse study populations would allow for more equitable results.
They also point out that support for these diverse studies must come from multiple levels across the scientific community, from individual researchers to funding agencies, journal editors, and governments (81, 82 
